# Independent CMC record review

Reviewer: delegated read-only cmc_review agent. Reviewed 2026-10-09.
Scope: twelve added CMC records, two structural parents and the focused actual
resolver/drafting-gateway regression test. No blocking findings.

The reviewer independently checked the final FDA M4Q subjects and current draft
M4Q(R2) status, evaluated existing consumers and initial-IND necessity flags,
and compared every original overlay entry with HEAD. All 115 original entries
remain unchanged. Their relative enumeration order remains unchanged; the new
entries now follow their appropriate existing P.2 and S.1 groups.

The actual default renderSectionBrief outputs were inspected. Full authoring
text is 763–848 characters and survives the 900-character cap. The final leaf
warning, phase/modality and provenance limits, expected-data suggestions and
pitfalls survive the default 3500-character brief; rendered briefs range from
1757 to 1896 characters. Parents and dependency codes are recognized. All fields
fit the existing CtdSection whitelist. The reviewer independently ran the new
focused suite: 27 passed.

A nonblocking initial finding identified that placing records first would make
the unsorted guidance API CMC-first. That layout was corrected by moving the
unchanged leaf blocks beside their parent groups. The reviewer reconstructed the
old layout in memory and reproduced its previous hash, proving that only record
placement changed, without modifying content.

Final reviewed SHA-256 pins:

| File | SHA-256 |
|---|---|
| server/services/ind/ctd/authoring-guidance.ts | 87875a27d80db335e166b9e055d0bf1699d7344e9019e0f05c36f42697fc0d26 |
| server/services/ind/ctd/ich-m4-headings.ts | c063ac55b664fb33a1dc20ba05fb3633cda8796f1eba214c45a7369dd2de6e2b |
| server/services/ana/__tests__/ind-cmc-leaf-drafting.test.ts | 02272be30798eb2b75c3fce84ff2d7eb09dafbc21b0a56152864a6eb8fc0022b |

This review confirms source-grounded recorded content, integration wiring and
scope boundaries. It does not qualify live model output, independent scientific
source review, product applicability, FDA acceptance or all-IND completeness.
